In 1963, Norwegian physician Kåre Berg discovered a new lipoprotein fraction in human blood that behaved differently from anything previously described. He named it lipoprotein(a) — Lp(a) — and noted that its levels varied dramatically between individuals. Sixty years later, we know that Lp(a) is present at elevated levels in approximately one in five people, that it roughly doubles the risk of heart attack and stroke, and that its level is almost entirely determined by genetics — not lifestyle.
We also know that most general practitioners have never tested their patients for it.
This is not a minor gap in standard care. Lp(a) elevation is the single most common inherited cardiovascular risk factor in the human population — more prevalent than familial hypercholesterolaemia, more genetically fixed than any metabolic risk factor, and now approaching an era of transformative therapies. If you do not know your Lp(a), you are missing a critical piece of your cardiovascular risk picture.
What Is Lipoprotein(a)?
Lp(a) is a lipoprotein particle with a unique and structurally complex composition. At its core, it resembles an LDL particle: it has a lipid core surrounded by a phospholipid monolayer and carries one molecule of Apolipoprotein B-100 (ApoB) on its surface. This is what makes Lp(a) atherogenic in the same way LDL is atherogenic — it deposits cholesterol in arterial walls and contributes to plaque formation.
But Lp(a) has a second, unique component that makes it more dangerous than standard LDL. Covalently linked to the ApoB-100 is a protein called apolipoprotein(a), or apo(a). Apo(a) is a large, highly polymorphic protein encoded by the LPA gene that is structurally homologous to plasminogen — the precursor to plasmin, the body's primary fibrinolytic (clot-dissolving) enzyme. This resemblance is not a coincidence, and it is not benign.
Because apo(a) looks like plasminogen, it competes with plasminogen for binding sites on fibrin clots and on the surface of endothelial cells. When Lp(a) occupies those binding sites, plasminogen cannot bind — and clot dissolution is impaired. The result is a prothrombotic state: clots form more easily, dissolve more slowly, and the risk of occlusive coronary events increases. This makes Lp(a) the only major lipoprotein with a dual atherogenic and thrombogenic mechanism.
Adding to this, Lp(a) carries an unusually high burden of oxidised phospholipids (OxPL) on its surface — arguably the most potent inflammatory lipid moiety in human blood. These OxPL activate endothelial inflammatory pathways, stimulate macrophage foam cell formation, and drive calcification in atherosclerotic plaques and aortic valve leaflets. The combination of atherosclerosis promotion, thrombosis promotion, and vascular inflammation makes Lp(a) one of the most multifaceted cardiovascular risk molecules known.
How Common Is Elevated Lp(a)?
Using the widely accepted threshold of 50 mg/dL (approximately 125 nmol/L) as the upper limit of normal, approximately 20% of the global adult population has elevated Lp(a). That translates to roughly 1.4 billion people worldwide — making it the single most prevalent genetic cardiovascular risk condition, substantially more common than familial hypercholesterolaemia (FH), which affects approximately 0.5% of the population.
Prevalence is not uniform across populations. Individuals of African descent have the highest median Lp(a) levels and highest rates of clinically significant elevation — affecting up to 30–40% in some studies. South Asian populations also have above-average Lp(a) levels, which may contribute to the elevated premature cardiovascular disease rates observed in this group. European and East Asian populations have somewhat lower median values, though 15–20% of these groups still fall above the clinical threshold.
The Risk Data: What Does High Lp(a) Actually Do?
The evidence base for Lp(a) as a causal cardiovascular risk factor is now exceptionally strong, combining observational epidemiology with Mendelian randomisation — the closest approximation to a randomised trial available in human genetics.
Large meta-analyses pooling data from over 100,000 individuals have consistently shown:
- ~2× increased risk of myocardial infarction in individuals with Lp(a) above the 80th percentile (approximately 50–60 mg/dL) compared to those in the lowest quintile
- ~1.4–1.7× increased risk of ischaemic stroke, driven primarily by the prothrombotic mechanism
- ~3× increased risk of aortic valve stenosis — a striking finding that reflects the unique OxPL-driven calcification mechanism of Lp(a)
- ~1.5× increased risk of peripheral arterial disease
Crucially, Mendelian randomisation studies using genetic variants at the LPAlocus as instrumental variables have confirmed that these associations are causal, not merely correlational. Individuals born with genetically higher Lp(a) have proportionally higher rates of cardiovascular events — and the relationship is dose-dependent and linear across the full Lp(a) distribution.
| Lp(a) Level | Approximate Risk Category | Risk Equivalent |
|---|---|---|
| < 30 mg/dL (< 75 nmol/L) | Low / normal | Background population risk |
| 30–50 mg/dL (75–125 nmol/L) | Borderline elevated | Modest elevation above baseline |
| 50–90 mg/dL (125–180 nmol/L) | Elevated (high risk) | ~1.5–2× increased CV event rate |
| > 90 mg/dL (> 180 nmol/L) | Very high risk | Equivalent to heterozygous familial hypercholesterolaemia |
The comparison to familial hypercholesterolaemia at very high Lp(a) levels is not rhetorical — it is the framing used in the EAS 2024 consensus statement. Patients with Lp(a) above 180 nmol/L should be regarded, treated, and monitored with the same urgency as patients with FH.
The Genetic Architecture of Lp(a)
Of all the major cardiovascular biomarkers, Lp(a) is the most genetically determined. Studies of twins, adopted individuals, and large population cohorts consistently find that 85–90% of the variance in Lp(a) levels between individuals is attributable to genetic factors — primarily variation at the LPA gene locus on chromosome 6q27.
The primary determinant of Lp(a) level is the number of kringle IV type 2 (KIV-2) repeat sequences in the apo(a) protein. Each person inherits two apo(a) isoforms — one from each parent. Individuals with fewer KIV-2 repeats produce a smaller apo(a) isoform that is more efficiently secreted by the liver, resulting in higher plasma Lp(a). Those with more repeats have a larger isoform that is less efficiently secreted, resulting in lower Lp(a). This inverse relationship between isoform size and Lp(a) level is well established and explains much of the population variability.
The practical implication is stark: diet cannot lower Lp(a). Exercise cannot lower Lp(a). Weight loss produces at most a 5–10% reduction in most studies — clinically insignificant for anyone meaningfully elevated. If your Lp(a) is high, it is high because of your DNA, and it will remain high unless a pharmacological intervention targets the gene or its transcript.
The Units Problem: mg/dL vs nmol/L
One of the practical complexities of Lp(a) testing is that laboratories report in two different units — mg/dL and nmol/L — and these are not straightforwardly interchangeable.
The fundamental issue is that apo(a) isoform size varies between individuals. A fixed-mass measurement (mg/dL) includes the mass of the apo(a) protein, which varies based on isoform size. Two people with identical Lp(a) particle numbers but different isoform sizes will have different mg/dL values, even though they carry the same atherogenic particle burden. nmol/L measurements, from isoform-independent assays, count particles directly and avoid this confound.
The EAS and most European labs now recommend nmol/L as the preferred unit. In the United States, many labs still report in mg/dL. A commonly used approximation is:nmol/L ≈ mg/dL × 2.5, but this is a rough estimate that can misclassify individuals at the margins. If your result is in mg/dL and near the threshold, request an nmol/L assay for definitive classification.
Who Should Test, and When?
The EAS 2024 consensus statement recommends that all adults should be tested for Lp(a) at least once in their lifetime. Because Lp(a) is genetically fixed, a single measurement in adulthood establishes your baseline for life.
Priority groups for immediate testing include:
- Anyone with a personal or family history of premature cardiovascular disease (before age 55 in men, before age 65 in women)
- Anyone with established cardiovascular disease who is pursuing aggressive risk reduction
- Anyone with familial hypercholesterolaemia (Lp(a) is particularly common and particularly dangerous in this group)
- Anyone considering statin therapy, where Lp(a) can reclassify intermediate-risk patients upward
- Anyone undergoing coronary artery calcium (CAC) scoring for risk stratification
- First-degree relatives of individuals with known high Lp(a) (50% inheritance probability)
The test requires a standard blood draw, is available at all major commercial labs, and costs $30–60 on a self-pay basis. Most insurance covers it with appropriate clinical indication.
What to Do If Your Lp(a) Is High
The near-term management of high Lp(a) — while awaiting approved specific therapies — focuses on aggressive reduction of all other modifiable cardiovascular risk factors:
Lower LDL-C aggressively. Since Lp(a) cannot be lifestyle-modified, the leverage comes from eliminating every other atherogenic driver. For patients with high Lp(a), many preventive cardiologists target LDL-C below 55 mg/dL (or ApoB below 60 mg/dL) using high-intensity statins, ezetimibe, and PCSK9 inhibitors as needed. PCSK9 inhibitors also produce a 20–30% reduction in Lp(a) as a secondary effect.
Optimise blood pressure. Target below 120/80 mmHg. The synergistic damage of high Lp(a) plus hypertension is particularly aggressive.
Eliminate smoking completely — smoking dramatically amplifies Lp(a)- related risk.
Control blood glucose and insulin resistance. Metabolic dysfunction compounds the prothrombotic effect of Lp(a).
Consider aspirin therapy — given the thrombogenic mechanism of Lp(a), antiplatelet therapy is plausibly beneficial, though net benefit depends on bleeding risk and should be individualised with your physician.
Emerging Therapies: The RNA Revolution
The therapeutic nihilism that once surrounded Lp(a) is being dismantled by RNA-based medicine. Several approaches targeting the LPA gene transcript are in advanced development:
Pelacarsen is a GalNAc-conjugated antisense oligonucleotide (ASO) that targets LPA mRNA in hepatocytes, silencing apo(a) production. Monthly subcutaneous injections reduce Lp(a) by 70–90% from baseline. Its Phase III cardiovascular outcomes trial — Lp(a)HORIZON — is ongoing, with results expected in 2025–2026. Regulatory submission is anticipated shortly after positive results.
Olpasiran (Amgen) is a GalNAc-conjugated siRNA that achieved >90% reduction in Lp(a) in Phase II trials with doses given every 12 weeks. Phase III trial (OCEAN[a]-OUTCOMES) is ongoing.
SLN360 (Silence Therapeutics) showed 98% reduction in Lp(a) in a single-dose Phase I trial. Phase II data are being generated.
These therapies are not yet approved as of October 2026, but the pipeline is unprecedented. If clinical outcomes trials confirm that lowering Lp(a) reduces events — as the Mendelian randomisation data strongly predicts — approved treatments could reach the market within 1–3 years. Every patient who knows their Lp(a) today is positioned to benefit immediately.
The Bottom Line
Lp(a) is the most common inherited cardiovascular risk factor in the human population. It is present in dangerous concentrations in 1 in 5 people. It doubles the risk of heart attack and stroke. It is almost entirely determined by your genetics — no diet or exercise will meaningfully change it. And transformative treatments are close.
You need to know your number. Request an Lp(a) test at your next blood draw. If you are elevated, do not panic — but do act. Bring every other risk factor to the lowest achievable level, monitor the treatment pipeline, and work with a physician who understands that Lp(a) is no longer a curiosity but a central piece of cardiovascular risk management.
The test costs $30–60 and can be done once in a lifetime. The information it provides is irreplaceable.